An H5N1 M2e-based multiple antigenic peptide vaccine confers heterosubtypic protection from lethal infection with pandemic 2009 H1N1 virus

Virology Journal

Volumn 7, Issue , 2010, Pages

  Zhao, Guangyu ^a   Sun, Shihui ^a   Du, Lanying ^b   Xiao, Wenjun ^a   Ru, Zhitao ^a,c   Kou, Zhihua ^a   Guo, Yan ^a   Yu, Hong ^a   Jiang, Shibo ^b   Lone, Yuchun ^c   Zheng, Bo Jian ^d   Zhou, Yusen ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b NEW YORK BLOOD CENTER   (United States)

^c INSERM   (France)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; FREUND ADJUVANT; H5N1 M2E BASED MULTIPLE ANTIGENIC PEPTIDE VACCINE; IMMUNOGLOBULIN G ANTIBODY; INFLUENZA VACCINE; UNCLASSIFIED DRUG; M2 PROTEIN, INFLUENZA A VIRUS; MATRIX PROTEIN; PEPTIDE;

ADJUVANT THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMBINATION CHEMOTHERAPY; CROSS REACTION; FEMALE; HISTOPATHOLOGY; INFLUENZA A (H1N1); MOUSE; NONHUMAN; PANDEMIC INFLUENZA; VIRUS REPLICATION; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; CHINA; CROSS PROTECTION; DISEASE MODEL; EPIDEMIC; HUMAN; IMMUNOLOGY; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H5N1; PHYSIOLOGY; PROTEIN TERTIARY STRUCTURE; VIROLOGY;

AVES; INFLUENZA A VIRUS; MUS; ORTHOMYXOVIRIDAE; SUIDAE; TETRA;

ANIMALS; CHINA; CROSS PROTECTION; DISEASE MODELS, ANIMAL; DISEASE OUTBREAKS; FEMALE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA A VIRUS, H5N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MICE; MICE, INBRED BALB C; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; VIRAL MATRIX PROTEINS;

EID: 77954409486     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-7-151     Document Type: Article

References (22)

1. Statement to the press by WHO Director-General Dr Margaret Chan:World now at the start of 2009 influenza pandemic. http://www.who.int/mediacentre/news/ statements/2009/h1n1-pandemic-phase6-20090611/en/print.html
2. Pandemic (H1N1) 2009 - update 100. http://www.who.int/csr/don/2010-05-14/ en/index.html
3. Cumulative Number of Confirmed Human Cases of Avian Influenza A/(H5N1) Reported to WHO. http://www.who.int/csr/disease/avian-influenza/country/cases- table-2010-05-06/en/index.html
4. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines - February 2010. WHO, Wkly Epidemiol Rec 85 100 107 20229648
5. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. RJ Garten CT Davis CA Russell B Shu S Lindstrom A Balish WM Sessions X Xu E Skepner V Deyde, et al. Science 2009 325 197 201 10.1126/science.1176225 19465683
6. Research and development of universal influenza vaccines. L Du Y Zhou S Jiang, Microbes Infect 12 280 286 10.1016/j.micinf.2010.01.001 20079871
7. A universal influenza A vaccine based on the extracellular domain of the M2 protein. S Neirynck T Deroo X Saelens P Vanlandschoot WM Jou W Fiers, Nat Med 1999 5 1157 1163 10.1038/13484 10502819
8. Efficient induction of mucosal and systemic immune responses by virus-like particles administered intranasally: implications for vaccine design. J Bessa N Schmitz HJ Hinton K Schwarz A Jegerlehner MF Bachmann, Eur J Immunol 2008 38 114 126 10.1002/eji.200636959 18081037
9. Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform. J Denis E Acosta-Ramirez Y Zhao ME Hamelin I Koukavica M Baz Y Abed C Savard C Pare C Lopez Macias, et al. Vaccine 2008 26 3395 3403 10.1016/j.vaccine.2008.04.052 18511159
10. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine. DG Eliasson K El Bakkouri K Schon A Ramne E Festjens B Lowenadler W Fiers X Saelens N Lycke, Vaccine 2008 26 1243 1252 10.1016/j.vaccine.2007.12.027 18243429
11. An influenza A vaccine based on tetrameric ectodomain of matrix protein 2. M De Filette W Martens K Roose T Deroo F Vervalle M Bentahir J Vandekerckhove W Fiers X Saelens, J Biol Chem 2008 283 11382 11387 10.1074/jbc.M800650200 18252707
12. Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin. JW Huleatt V Nakaar P Desai Y Huang D Hewitt A Jacobs J Tang W McDonald L Song RK Evans, et al. Vaccine 2008 26 201 214 10.1016/j.vaccine.2007.10.062 18063235
13. Heterosubtypic protection against pathogenic human and avian influenza viruses via in vivo electroporation of synthetic consensus DNA antigens. DJ Laddy J Yan M Kutzler D Kobasa GP Kobinger AS Khan J Greenhouse NY Sardesai R Draghia-Akli DB Weiner, PLoS One 2008 3 2517 10.1371/journal.pone.0002517 18575608
14. Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys. J Fan X Liang MS Horton HC Perry MP Citron GJ Heidecker TM Fu J Joyce CT Przysiecki PM Keller, et al. Vaccine 2004 22 2993 3003 10.1016/j.vaccine.2004.02.021 15297047
15. Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2. K Mozdzanowska J Feng M Eid G Kragol M Cudic L Otvos Jr W Gerhard, Vaccine 2003 21 2616 2626 10.1016/S0264-410X(03)00040-9 12744898
16. Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. JP Tam, Proc Natl Acad Sci USA 1988 85 5409 5413 10.1073/pnas.85.15.5409 3399498
17. Long-term high-titer neutralizing activity induced by octameric synthetic HIV-1 antigen. CY Wang DJ Looney ML Li AM Walfield J Ye B Hosein JP Tam F Wong-Staal, Science 1991 254 285 288 10.1126/science.1925584 1925584
18. An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. G Zhao Y Lin L Du J Guan S Sun H Sui Z Kou CC Chan Y Guo S Jiang, et al. Virol J 7 9 10.1186/1743-422X-7-9 20082709
19. Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments. M Schotsaert M De Filette W Fiers X Saelens, Expert Rev Vaccines 2009 8 499 508 10.1586/erv.09.6 19348565
20. Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. A Jegerlehner N Schmitz T Storni MF Bachmann, J Immunol 2004 172 5598 5605 15100303
21. Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein. R Wang A Song J Levin D Dennis NJ Zhang H Yoshida L Koriazova L Madura L Shapiro A Matsumoto, et al. Antiviral Res 2008 80 168 177 10.1016/j.antiviral.2008.06.002 18598723
22. Sequence comparison between the extracellular domain of M2 protein human and avian influenza A virus provides new information for bivalent influenza vaccine design. W Liu P Zou J Ding Y Lu YH Chen, Microbes Infect 2005 7 171 177 10.1016/j.micinf.2004.10.006 15777646